UBS analyst Vilas Abraham maintains Ready Capital (NYSE:RC) with a Neutral and raises the price target from $11 to $11.5.
TG Therapeutics Announces Combination Data Presentations At The XIX International Workshop On Chronic Lymphocytic Leukemia
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced data presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL). Data highlights from each presentation are included below.
The Company